Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- 79 Investigational Drugs for Alzheimer's Disease in Clinical Stage: PhRMA Report
December 13, 2010
- Astellas to Transfer Marketing of Protopic to Maruho
December 13, 2010
- Axitinib Extends PFS in mRCC Patients: Pfizer
December 13, 2010
- Ketotifen to Be Reclassified as Class 2 OTC Drug
December 13, 2010
- Takeda Licenses Baxter's Vero-Cell Based Flu Vaccine Technology
December 13, 2010
- BMS Confirms Non-Inferiority of SC Injection of Orencia
December 13, 2010
- Merck Serono Aims at 15% Growth in 2010-2014: President Smith
December 13, 2010
- Shionogi Licenses Ophthalmic Peptide Vaccines from OncoTherapy
December 13, 2010
- BIBF1120 Inhibits Lowering of FVC: BI
December 13, 2010
- NBI Takes Over Mobic Marketing from Daiichi Sankyo
December 13, 2010
- Lubiprostone Shows Favorable Safety, Tolerability in PIII: Sucampo, Abbott
December 13, 2010
- Sales of Class 1 OTC Drugs Up 8.9% in October: JSMI
December 13, 2010
- Otsuka HD's Market Capitalization to Exceed \1 Tril.
December 13, 2010
- JPMA Campaign Highlights Non-approved Drugs
December 13, 2010
- Kyorin Turns Down New Proposal from Sawai
December 13, 2010
- Daiichi Sankyo, Kitasato to Set Up Vaccine JV
December 13, 2010
- JPMA Allies with Patients' Groups for Lobbying
December 13, 2010
- Astellas Establishes Global Oncology Strategy Unit
December 13, 2010
- Ain Pharmaciez: Half-Year Sales Up 3.5% to \61.8 Bil.
December 13, 2010
- Takeda Applies for Higher Leuplin Dosage Based on Published Evidence
December 13, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…